Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
The National Cancer Institute is inviting applications for a grant aimed at validating biomarkers and assays used in cancer detection, diagnosis, prognosis, and treatment. This opportunity focuses on both analytical and clinical validation of these assays, which must work on human samples. The UH2 phase involves analytical validation over 2 years, while the UH3 phase covers clinical validation…
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications to support the validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction…
Funding Source
Awards & funding
Dates
Documents
Secure Grant Funding 10x Faster
Scout delivers AI-powered grant writing paired with experts that's faster, more affordable, and built to win.
Already have an account? Sign In
Trusted by 500+ Happy Customers